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Abstract
Milk fat globule-epidermal growth factor factor 8 (MFG-E8) regulates innate immune function by modulating cellular
signaling, which is less understood. Herein, we aimed to investigate the direct anti-inflammatory role of MFG-E8 in
macrophages by pre-treatment with recombinant murine MFG-E8 (rmMFG-E8) followed by stimulation with LPS in
RAW264.7 cells and in peritoneal macrophages, isolated from wild-type (WT) or MFG-E8
2/2 mice. RAW264.7 cells and
mouse peritoneal macrophages treated with rmMFG-E8 significantly downregulated LPS-induced TNF-a mRNA by 25%
and 24%, and protein levels by 29% and 23%, respectively (P,0.05). Conversely, peritoneal macrophages isolated from
MFG-E8
2/2 mice produced 28% higher levels of TNF-a,a sc o m p a r e dt oW Tm i c ew h e nt r e a t e dw i t hL P S .I nin vivo,
endotoxemia induced by intraperitoneal injection of LPS (5 mg/kg BW), at 4 h after induction, serum level of TNF-a was
significantly higher in MFG-E8
2/2 mice (837 pg/mL) than that of WT (570 pg/mL, P,0.05). To elucidate the direct anti-
inflammatory effect of MFG-E8, we examined STAT3 and its target gene, SOCS3. Treatment with rmMGF-E8 significantly
induced pSTAT3 and SOCS3 in macrophages. Similar results were observed in in vivo treatment of rmMFG-E8 in
peritoneal cells and splenic tissues. Pre-treatment with rmMFG-E8 significantly reduced LPS-induced NF-kBp 6 5
contents. These data clearly indicated that rmMFG-E8 upregulated SOCS3 which in turn interacted with NF-kB p65,
facilitating negative regulation of TLR4 signaling for LPS-induced TNF-a production. Our findings strongly suggest that
MFG-E8 is a direct anti-inflammatory molecule, and that it could be developed as a therapy in attenuating inflammation
and tissue injury.
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Introduction
The glycoprotein, MFG-E8 is mainly secreted by mononuclear
cells, and participates in the phagocytosis of apoptotic cells by
tethering between phosphatidylserine (PS) on apoptotic cells and
avb3-integrin on phagocytes [1]. Detrimental autoimmune diseas-
es are likely to be seen in MFG-E8
2/2 mice due to the infiltration
of apoptotic cells at the germinal centers of spleen [2,3]. With the
concept of removing the dead cells from various organs, MFG-E8
has proved to be an essential factor in controlling the progression
of various inflammatory diseases [4,5]. However, recent studies
showed that MFG-E8-mediated potential therapeutic benefits in
sepsis and intestinal injury were not only solely dependent on the
enhanced clearance of apoptotic cells, but also rely on diverse
cellular events to maintain the epithelial integrity and healing of
the injured mucosa via protein kinase C (PKC) pathways [6].
Furthermore, MFG-E8-mediated upregulation of Akt, twist and
MAP kinase signaling to perform several intra-cellular functions
has also been reported [7,8].
In mammals, Toll like receptor (TLR) 4 expressed in immune-
reactive cells can efficiently recognize bacterial lipopolysaccharide
(LPS) and trigger down-stream signaling via several adaptor
molecules, e.g., myeloid differentiation factor 88 (MyD88), Toll/
IL-1 receptor domain-containing adaptor (TIRAP)/MyD88-
adaptor-like (Mal), IL-1 receptor-associated kinase (IRAK), and
TNF receptor-associated factor 6 (TRAF6) to induce NF-kB,
MAP kinases and JNK pathways. This in turn upregulates the
expression of pro-inflammatory cytokines, e.g., tumor necrosis
factor (TNF)-a [9,10]. Uncontrolled activation of innate immune
system by LPS may cause ‘‘endotoxin shock’’ [11], attributing a
tightly controlled mechanism for its regulation. To maintain the
fine-tuned balance of TLR4 pathway, several intracellular
negative regulators, e.g., A20, IRAK-M, and Tollip are also
become activated under LPS-treated conditions [12,13].
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onSignal transducer and activator of transcription (STAT) 3 is
known to play essential roles in maintaining the homeostatic
balance between pro- and anti-inflammatory signals in immune
competent cells induced by a wide ranges of cytokines, interleukin
(IL)-5, 6, 10, interferon (IFN)-c, epidermal growth factor (EGF),
hepatocyte growth factor (HGF), hormones (prolactin, leptins)
and other factors, leukemia inhibitory factor (LIF), bone
morphogenetic protein (BMP)-2 [14–16]. Although there are
seven members of STAT proteins available in cellular systems,
the role of STAT3 is widely described in the field of innate-
immune system induced by those cytokines and growth factors.
The activation of STAT3 by various ligands occurs by binding to
their respective receptors and receptor-associated kinases. The
binding of IL-6 family of cytokines to the gp130 receptor triggers
STAT3 phosphorylation by janus kinase (JAK) 2 [17]. Epidermal
growth factor receptor and certain other receptor tyrosine
kinases, such as c-MET, phosphorylate STAT3 in response to
their ligands [18]. STAT3 is also a target of the c-Src non-
receptor tyrosine kinase induced by various ligands [19]. Since
STAT3-deficient mice are lethal [20], studies in conditional
knock-out mice containing STAT3-deficient monocytes and
neutrophils showed a reduced survival from endotoxic shock
[21,22]. An intriguing feature of STAT3 signaling lies with the
fact that its function is firmly controlled by the STAT-induced
STAT inhibitor (SSI) family of proteins, that are also known as
suppressor of cytokine signaling (SOCS). In mammals, eight
members of the SOCS proteins (SOCS1-7 and CIS) have been
reported [23]. SOCS1 and 3 possess a kinase-inhibitory region
(KIR) domain that is critical for inhibition of kinase activity [24].
In addition, over-expression studies have shown that both
SOCS1 and 3 exhibit negative regulatory effects on TLR4
signaling [25]. Recent reports demonstrated that LPS-induced
pro-inflammatory cytokine production and NF-kBa c t i v a t i o na r e
inhibited in cells over-expressing SOCS proteins [25,26]. Several
adaptor molecules that bridge between TLR4 and NF-kB, e.g.,
MAL/TIRAP, IRAK1 are the target of SOCS for ubiquitination
and proteasomal degradation, resulting in abrogation of NF-kB
activation [26–28]. Moreover, SOCS1 proteins are also known to
regulate TLR-induced NF-kB activation by direct interaction
with p65 subunit of NF-kB, causing downregulation of p65
protein levels by ubiquitin-mediated degradation [29].
Although MFG-E8 is a potential therapeutic agent in terms of
downregulating the expression of pro-inflammatory cytokines in
various inflammatory conditions [5,30–32], the mechanisms
underlying these features were not clearly elucidated. Herein, we
aimed to evaluate the direct anti-inflammatory effects of MFG-E8
on LPS-induced TNF-a production in macrophages and focused
on its plausible mechanism by which MFG-E8 transduce down-
stream signaling for attenuating inflammation.
Materials and Methods
Experimental animals
Male weight (25–30 g) and age-matched wild-type (WT)
C57BL/6J mice purchased from Taconic, Albany, NY and
MFG-E8
2/2 mice obtained as a kind gift from Dr. Shigekazu
Nagata, Kyoto University, Japan, were housed in a temperature-
controlled room on a 12 h light-to-dark cycle and fed a standard
laboratory diet. Animal experimentation was carried out in
accordance with the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources). The project
was approved by the Institutional Animal Care and Use
Committee (IACUC) of The Feinstein Institute for Medical
Research.
Mouse peritoneal macrophage isolation and culture
The mice were euthanized by isoflurane inhalation, and then
thioglycollate-elicited peritoneal exudates were collected by
washing with ice-cold Ca
2+ and Mg
2+-free Hank’s Balanced Salt
Solution (HBSS), with 10% FBS and 100 units/mL each of
penicillin (Invitrogen, CA) and streptomycin (Invitrogen). Col-
lected peritoneal fluids were centrifuged at 400 g for 10 minutes
(min) at 4uC and the resulting pellet was dissolved in 200 ml of red
blood cell (RBC) lysis reagent for 2–3 min at 37uC. After
centrifugation and washing with cold PBS, the RBC free pellet
was dissolved in culture medium consisting of RPMI 1640
(Invitrogen) supplemented with 25 mM HEPES, 2 mM gluta-
mine, 10% fetal bovine serum (FBS; Solon, Ohio), penicillin
(100 IU/ml), and streptomycin (100 IU/ml). Peritoneal macro-
phages were then allowed to adhere in 24-well microplates at a
density of 1610
6 cells/mL for 2 h at 37uC in a 5% CO2. Non-
adherent cells were removed by washing with pre-warmed culture
medium, and used in subsequent in vitro studies.
Mouse model of endotoxemia
WT and MFG-E8
2/2 mice were intraperitoneally (i.p.) injected
with LPS (Escherichia coli O55:B5, Difco Laboratories, Detroit, MI)
at a dose of 5 mg/kg BW for 4 h, and then blood was drawn from
the inferior vena-cava. Serum was separated from whole blood by
centrifugation at 4000 g and used for TNF-a ELISA. Mice
injected with equal volume of saline instead of LPS served as sham
control. To assess splenic TNF-a content, LPS (5 mg/kg BW) was
i.p. injected into WT and MFG-E8
2/2 mice, and then they were
euthanized and the spleen harvested. Total RNA was extracted
from 10 mg of splenic tissues, following reverse transcription,
TNF-a mRNA expression was measured by real-time PCR using
specific primers. Protein levels of TNF-a from the splenic tissue
samples were examined by using ELISA from the whole tissue
lysates.
Cell line and culture condition
Mouse macrophage cell line, RAW264.7 cells obtained from
American Type Culture Collection (ATCC), were cultured in
DMEM media (Invitrogen) with 10% FBS and penicillin and
streptomycin and kept in 37uC incubator under humidified
condition containing 5% CO2.
In vivo and in vitro treatment of recombinant murine
MFG-E8 (rmMFG-E8)
WT mice were injected with rmMFG-E8 (R&D Systems,
Minneapolis) at a dose of 0.4 mg/20 g BW via i.p. for 2 h. The
subsequent studies were carried-out by initiating endotoxemia in
mice with an overdose of LPS (5 mg/kg BW) injection into the
peritoneal cavity. For in vitro experiments, peritoneal macrophages
and RAW264.7 cells were pre-treated with 500 ng/mL rmMFG-
E8 for 2 h, followed by LPS (10 ng/mL) stimulation, and used in
several experiments.
Quantitative real-time PCR
Total RNA extracted from mouse peritoneal macrophages and
RAW264.7 cells by using the Trizol reagent (Invitrogen) was
reverse-transcribed into cDNA. TNF-a and b-actin real-time PCR
was performed using 7300 Real-Time PCR system (Applied
Biosystems) with the primer sequences for TNF-a (NM_013693.2)
forward: 59-AGA CCC TCA CAC TCA GAT CAT CTT C-39,
reverse: 59-TTG CTA CGA CGT GGG CTA CA-39; and b-actin
(NM_007393.3) forward: 59-CGT GAA AAG ATG ACC CAG
ATCA-39, reverse: 59-TGG TAC GAC CAG AGG CAT ACA G-
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0.1 mmol of each forward and reverse primers, 2 mg cDNA and
12.5 ml SYBR Green PCR Master Mix (Roche Diagnostics,
Indianapolis, IN). The gene expression was normalized with that
of b-actin as internal control and expressed as relative change to
untreated samples.
Enzyme-linked immunosorbent assay (ELISA)
TNF-a and IL-1b from the mouse macrophage cell culture
supernatants pre-treated with and without rmMFG-E8 and
treated with LPS were measured by ELISA using manufacturer’s
instructions (BD Biosciences, CA).
Western blot analysis
Protein extraction and Western-blot assays were performed as
described previously [30]. Briefly, RAW264.7 cells and spleen
tissue samples were completely lysed in 10 mM Tris-HCl, pH 7.6,
containing 2 mM Na orthovanadate pH 7.6, 0.2 mM PMSF,
2 mg/ml leupeptin, 2 mg/ml aprotinin and 1 tablet of Complete
Mini (Roche Diagnostic, IN, USA). Equal amount of protein per
lane was loaded into the 4–12% Bis-Tris gel (Invitrogen) and
transferred to a 0.2-mm nitrocellulose membrane (Invitrogen). The
membrane was incubated for overnight at 4uC with the primary
antibodies (Ab) as obtained from respective vendors: rabbit anti-
mouse pSTAT3 monoclonal Ab, and rabbit anti-mouse SOCS3
monoclonal Ab from Cell Signaling Technology, Danvers, MA
and rabbit anti-mouse NF-kB (p65) from Santa Cruz Biotechnol-
ogy, CA at a 1:1000 dilution, reacted with peroxidase-conjugated
goat anti-rabbit secondary Ab (Southern Biotech, AL) at a
1:10,000 dilution at RT for 2 h, and washed five times in TBST.
The resulting signals were detected by ECL (GE Healthcare,
Buckinghamshire, UK). The immunoblot was washed and
reprobed with mouse anti-b-actin Ab (Sigma-Aldrich, St. Louis,
MO) as an internal control.
Immunoprecipitation assay
Immunoprecipitation was performed as described previously
[31]. Briefly; RAW264.7 cells were lysed in buffer containing
150 mM NaCl, 1% Nonidet P-40, 50 mM Tris HCl (pH 8.0), and
1 mM PMSF; and a total of 80 mg protein was pre-cleared for 1 h
at 4uC with protein G-Sepharose beads (GE Healthcare). Pre-
cleared extracts were immunoprecipitated overnight at 4uC with
anti-mouse SOCS3 Ab and rabbit anti-mouse NF-kB (p65),
followed by 1 h incubation with 50% slurry of protein G beads at
4uC in a mild rotating shaker, the beads were recovered by
spinning at 10,000 g for 1 min. After 5 times washing, the beads
were re-suspended in 30 ml of sample buffer and were subjected to
Western blotting using anti-p65 Ab and rabbit anti-mouse
Ubiquitin Ab (Cell Signaling Technology).
Preparation of cytoplasmic and nuclear extract
Cytoplasmic and nuclear extracts were prepared as described
previously [33]. RAW264.7 cells in 10-cm dishes were treated with
rmMFG-E8 for 2 h, and then stimulated with LPS for 30 min.
Cells were then washed two times with ice-cold phosphate-
buffered saline (PBS) and resuspended in 250 ml of homogeniza-
tion buffer containing 10 mM HEPES at pH 7.2, 3 mM MgCl2,
10 mM KCl, 3 mM NaCl, 1 mM EDTA, 1 mM EGTA (pH 7.5),
0.5 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, and 2 mM
Na orthovanadate (pH 7.6). The cells were allowed to swell on ice
for 15 min, lysed gently with 12.5 ml of 10% NP-40, and
centrifuged at 10,000 g for 10 min at 4uC. The supernatant was
collected and used as the cytoplasmic extracts. The nuclear pellet
was resuspended in 60 ml of nuclear extraction buffer containing
20 mM HEPES, pH 7.2, 1 mM MgCl2, 800 mM KCl, 25%
glycerol, 0.5 mM EDTA, 1% NP-40, 0.5 mM PMSF, 1 mg/ml
leupeptin, 1 mg/ml aprotinin, 2 mM Na orthovanadate (pH 7.6),
agitated for 30 min at 4uC, and the nuclear debris was centrifuged
at 10,000 g for 15 min. The supernatant (nuclear extract) was
collected, frozen in liquid nitrogen and stored at 280uC until
ready for analysis. Protein concentration was determined using
Bradford reagent. Both the cytoplasmic and nuclear proteins were
subjected to Western blotting using anti-p65 Ab, and reprobed
with anti-GAPDH Ab (Santa Cruz Biotechnology) and anti-
Histone Ab (Cell Signaling Technologies), respectively.
Statistical analysis
Data are expressed as means 6 SE and compared by one-way
ANOVA and Student-Newman-Keuls (SNK) test. Student t test
was used when only two groups were compared. Differences in
values were considered significant if p,0.05.
Results
Pre-treatment of rmMFG-E8 attenuates LPS-induced
TNF-a production in macrophages
To determine the beneficial effects of MFG-E8, RAW264.7
cells as well as mouse peritoneal macrophages were incubated with
rmMFG-E8, followed by the stimulation with LPS and TNF-a
levels were assessed. As shown in Fig. 1A and 1B, RAW264.7 cells
treated with LPS dramatically induced the TNF-a, while pre-
treatment of rmMFG-E8 significantly reduced the LPS-induced
TNF-a mRNA and protein levels by 25% and 29%, respectively.
Similar effects were also observed in peritoneal macrophages from
WT mice, where the cells treated with rmMFG-E8 significantly
downregulated the LPS-induced TNF-a mRNA and protein levels
by 24% and 23%, respectively (Fig. 1C, 1D).
MFG-E8 is abundantly expressed in macrophages. To reveal
the role of endogenous MFG-E8, peritoneal macrophages isolated
from MFG-E8
2/2 mice were treated with LPS and then TNF-a
production was assessed. We noticed that in LPS-treated
conditions TNF-a mRNA and protein in peritoneal macrophages
isolated from the MFG-E8
2/2 mice were found to be significantly
higher by 28% and 42% than those in WT, respectively (Fig. 1C,
1D).
Previously, several in vitro studies on immune reactive cells have
been performed in an optimized dose of 500 ng/ml of rmMFG-E8
[31,34]. Although supportive evidences exist, we carried out a pilot
study where the dose dependent effects of rmMFG-E8 was
evaluated in the context of downregulation of LPS-induced TNF-a
production in murine peritoneal macrophages. Our results showed
that the macrophage cells treated with 1000 and 500 ng/ml of
rmMFG-E8 were able to exhibit significant downregulation of
LPS-induced TNF-a production. On the other hand, no such
significant effects were observed at lower doses of rmMFG-E8 (250
and 125 ng/ml) (Fig. 1E). We therefore, performed our in vitro
studies in macrophages with 500 ng/ml of rmMFG-E8. Con-
versely, to attain the maximum response of rmMFG-E8 for
downregulating the LPS-induced TNF-a production in macro-
phages, we optimized the LPS concentration by stimulating the
murine macrophage cells at various concentrations of LPS while
keeping the rmMFG-E8 pre-treatment dose and incubation time
constant. We noticed that the rmMFG-E8-mediated significant
reduction of TNF-a levels in macrophages, was obtained at
10 ng/ml of LPS stimulation but not in lower doses (,10 ng/ml)
(data not shown). Hence we selected the 10 ng/ml of LPS dose for
subsequent in vitro studies.
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cytokines and chemokines are also critical. While doing the in vitro
experiments, we noticed that the RAW264.7 cells did not produce
IL-1b, IL-6 and IL-10 if treated with LPS alone, but rather
required stimulation with LPS in combination with interferon-c
(IFN-c). We therefore, using the murine peritoneal macrophages
evaluated the effects of rmMFG-E8 in terms of downregulating the
production of pro-inflammatory cytokine, other than TNF-a.
According to our results, we found that the pre-treatment of
rmMFG-E8 significantly downregulated the IL-1b levels (34.2%)
in LPS treated WT murine peritoneal macrophages (Fig. 1F). In
contrast, the IL-1b contents were significantly higher (37%) in
LPS-treated peritoneal macrophages isolated from MFG-E8
2/2
mice as compared to WT animals (Fig. 1F). Taken together, these
results demonstrated the novel anti-inflammatory roles of MFG-
E8 as generated not only by downregulating the TNF-a but also
by reducing IL-1b levels in macrophages.
Mice pre-treated with rmMFG-E8 were protective against
LPS-induced endotoxemia by reducing TNF-a
We have previously demonstrated that during sepsis or in LPS-
treated conditions, endogenous MFG-E8 expression in the spleen,
macrophages and in circulation was dramatically reduced [34,35].
To compensate the deficit of MFG-E8 that occurred during LPS-
treatment, we administered rmMFG-E8 exogenously into the WT
mice and examined its effects in TNF-a production during
Figure 1. Effect of rmMFG-E8 on TNF-a production by LPS treated macrophages. (A, B) RAW264.7 cells (1610
6 cells) and (C, D) peritoneal
macrophages from WT and MFG-E8
2/2 mice (0.5610
6 cells) were plated in 24-well cell culture plates. After pre-incubation with rmMFG-E8 (500 ng/
mL) for 2 h, the cells were then stimulated by LPS (10 ng/mL) for 2 h and the expression of TNF-a mRNA (A, C) was checked by real-time PCR. To
assess the protein levels of TNF-a (B, D), RAW264.7 cells and mouse peritoneal macrophages were stimulated with LPS for 4 and 24 h, respectively
and then ELISA was performed from the culture supernatants. (E) Dose-dependent effects of rmMFG-E8 for inhibiting the LPS-induced TNF-a
production in murine peritoneal macrophages (0.5610
6 cells) cultured in 24-well cell culture plates. (F) Peritoneal macrophages from WT and MFG-
E8
2/2 mice (0.5610
6 cells) were plated in 24-well cell culture plates. After pre-incubation with rmMFG-E8 (500 ng/mL) for 2 h, the cells were
stimulated by LPS for 24 h, followed by the measurement of IL-1b by ELISA. Data are expressed as means 6 SE (n=3 independent experiments) and
compared by one-way ANOVA and SNK method: *P,0.05 vs. control;
#P,0.05 vs. LPS and compared to rmMFG-E8;
{P,0.05 vs. LPS and compared to
MFG-E8
2/2.
doi:10.1371/journal.pone.0027685.g001
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rmMFG-E8 showed a significant decrease in serum levels of TNF-
a after in vivo LPS administration as compared to vehicle treated
mice. Conversely, the i.p. LPS injection markedly increased the
serum contents of TNF-a in MFG-E8
2/2 mice as compared to
the WT counterparts (Fig. 2A); hence showing concordance with
our in vitro results using peritoneal macrophages from these two
groups of mice (Fig. 1C, 1D).
MFG-E8 serves as an essential factor for the phagocytic
engulfment of apoptotic cells by macrophages. Studies with
MFG-E8
2/2 mice showed infiltrating apoptotic cells at the
germinal centers of spleen [2,3]. Considering that the spleen as
one of the vital organs in innate immune system, we noticed an
enlarged size and weight of the spleen in MFG-E8
2/2 mice as
compared to the WT mice (data not shown), pointing to the
possibility of an abnormal immune function in the spleen of those
mice groups. Hence, we intended to compare the splenic contents
of TNF-a in endotoxemic mice treated with rmMFG-E8. Our
results showed that the mRNA and protein levels of TNF-a in
rmMFG-E8 treated WT mice were significantly reduced as
compared to non-treated mice with endotoxemia (Fig. 2B, 2C).
Furthermore, although significant induction of TNF-a levels in
both WT and MFG-E8
2/2 mice in the spleen was observed after
i.p. endotoxin challenge, the levels were comparatively higher in
MFG-E8
2/2 mice than those in WT mice (Fig. 2B, 2C).
Collectively, these evidences strongly supported the notion of
MFG-E8-mediated downregulation of TNF-a production in
endotoxemia.
STAT3 is activated in macrophages after rmMFG-E8
pre-treatment
To address the mechanisms by which MFG-E8 functions to
downregulate the LPS-induced TNF-a production in macrophag-
es, we performed in vitro experiments using RAW264.7 cells and
mouse peritoneal macrophages. Within 2 h of rmMFG-E8
treatment, the phosphorylation of STAT3 (pSTAT3) was
significantly induced in RAW264.7 cells (Fig. 3A), and in mouse
peritoneal macrophages (Fig. 3B). However, LPS can also robustly
induce the pSTAT3 levels in 2 h, which may further implicate it as
a potent transcription factor for increasing TLR4-mediated TNF-
a production (Fig. 3C). Next, we attempt to examine the status of
STAT3 in conditions where the cells were pre-treated with
rmMFG-E8, followed by exposure with LPS. As shown in Fig. 3D,
using RAW264.7 cells, we noticed that LPS-induced STAT3
activation started from 2 h and commenced up to prolonged time
course of at least 6 h. An interesting feature as evident from our
study revealed that when the cells were pre-treated with rmMFG-
E8, the overall LPS effects for STAT3 activation become reduced
at least in part in a time course dependent manner (Fig. 3D). This
could be due to the fact that the pre-treatment of rmMFG-E8 may
induce the expression of down-stream negative regulator(s) to
interfere with the LPS-induced STAT3 signaling.
To verify the STAT3 roles as a down-stream mediator for LPS-
induced optimal TNF-a production, we used a chemical inhibitor
of STAT3, Static, to treat RAW264.7 cells and then LPS effects
for TNF-a expression were assessed. With an optimized dose of
Static at which it inhibits STAT3 phosphorylation without
affecting the cell viability, we noticed that the effects of LPS on
TNF-a mRNA and protein were decreased in Static-treated cells
as compared to the DMSO-treated controls (Fig. 3E, 3F),
suggesting the requirement of STAT3 for LPS-induced optimal
TNF-a production in macrophages. Furthermore, due to the
blocking of STAT3 functions by Static, we noticed that the
beneficial effects of MFG-E8 for downregulating the LPS-induced
TNF-a production was diminished, suggesting the pivotal role of
STAT3 for MFG-E8-mediated downregulation of TNF-a contents
(Fig. 3E, 3F). Therefore, STAT3 may provide dual roles: one as
the LPS induced pro-inflammatory factor, while the other as the
MFG-E8- mediated anti-inflammatory signal.
MFG-E8 pre-treatment upregulates SOCS3 expression in
macrophages
To reveal whether MFG-E8 plays any role in activating the
down-stream negative regulator, RAW264.7 cells were treated
Figure 2. In vivo effects of rmMFG-E8 in controlling TNF-a
production during endotoxemia. (A) WT mice were injected with
rmMFG-E8 (0.4 mg/20 g BW) via i.p. for 2 h and then endotoxemia was
generated by an overdose of i.p LPS (5 mg/kg BW) administration.
Similarly, in another experiment, WT and MFG-E8
2/2 mice were treated
with LPS (5 mg/kg BW) via i.p.. After 4 h, mice were euthanized, blood
was collected and TNF-a measured by ELISA. (B, C) WT mice were
treated with rmMFG-E8 (0.4 mg/20 g BW) for 2 h, followed by LPS
(5 mg/kg BW) challenge. WT and MFG-E8
2/2 mice were injected with
LPS (5 mg/kg BW) i.p.. After 2 h total RNA and after 4 h proteins were
extracted from splenic tissues for TNF-a expression using real-time PCR
and ELISA, respectively. All data are expressed as means 6 SE (n=3
independent experiments) and compared by one-way ANOVA and SNK
method: *P,0.05 vs. sham control;
#P,0.05 vs. endotoxemia and
compared to rMFG-E8 treatment;
{P,0.05 vs. endotoxemia and
compared to MFG-E8
2/2.
doi:10.1371/journal.pone.0027685.g002
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SOCS3 expression at the mRNA and protein levels (Fig. 4A, 4B).
Similar results were also observed in murine peritoneal macro-
phages (Fig. 4C, 4D). During LPS treatment, RAW264.7 cells
dramatically induced the SOCS3 expression at its transcriptional
and translational levels, while the effects of LPS for SOCS3
become significantly decreased if the cells were pre-treated with
rmMFG-E8 (Fig. 4E, 4F). This would suggest the possibility of
negative regulation of TLR4 cascades mediated by SOCS3 that
was upregulated during the 2 h rmMFG-E8 pre-treatment.
In vivo LPS exposure augments STAT3 and SOCS3 in
mouse peritoneal cells and splenic tissues
To evaluate the in vivo status of STAT3 and SOCS3 levels in
endotoxemic mice after pre-treatment with rmMFG-E8, we
carried out Western blot for phospho and total STAT3 levels
Figure 3. MFG-E8 activates pSTAT3. Western-blot for pSTAT3 was done in extracted total proteins from (A) RAW264.7 cells (4610
6 cells) and (B)
mouse peritoneal macrophages (2610
6 cells) grown in 6-well plate and treated with rmMFG-E8 (500 ng/mL) for 2 h. (C) RAW264.7 cells were cultured
and then stimulated with LPS (10 ng/mL) for 2 h. Western-blot analysis was performed from 25 mg of extracted proteins from the above described
experiments using anti-mouse pSTAT3 Ab. The immunoblots were stripped and reprobed with anti-mouse STAT3 Ab. The images shown are
representatives of 3 independent experiments. Densitometric evaluations (pSTAT3/STAT3) are expressed as means 6 SE and compared by one-way
ANOVA and SNK method: *P,0.05 vs. control. (D) Total protein was extracted from RAW264.7 cells (1610
6 cells) grown in 24-well culture plates and
treated with rmMFG-E8 (500 ng/mL) and LPS (10 ng/mL) at different time points, and Western-blot for pSTAT3 and STAT3 was performed as
described above. A representative autoradiograph is also shown. Densitometric evaluations (pSTAT3/STAT3) are expressed as means (n=3) 6 SE and
compared by one-way ANOVA and SNK method: *P,0.05 vs. LPS at 0 h;
#P,0.05 vs. LPS at corresponding time points. (E, F) RAW264.7 cells (1610
6
cells) were cultured in a 24-well cell culture plate and treated with Static (6.25 mM) for overnight, followed by pre-treatment with rmMFG-E8 (500 ng/
mL) for 2 h and stimulated with LPS (10 ng/mL) for another 4 h. TNF-a mRNA and protein were measured by real-time PCR and ELISA, respectively.
For real-time PCR, b-actin served as the internal control. Data are expressed as means (n=3) 6 SE and compared by one-way ANOVA and SNK
method: *P,0.05 vs. LPS (2);
#P,0.05 vs. LPS (+).
doi:10.1371/journal.pone.0027685.g003
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peritoneal cells and splenic tissues. After 2 h of rmMFG-E8 pre-
treatment, pSTAT3 become significantly increased in peritoneal
cells and splenic tissues (Fig. 5A, 5B). Moreover, we also noticed
that the mice treated with LPS showed dramatic induction of
pSTAT3 levels in those samples, while that was comparatively
lower in endotoxemic mice pre-treated with rmMFG-E8 in vivo
(Fig. 5A, 5B). Consistent with the above findings, we also obtained
similar trend in results for SOCS3 gene expression in splenic tissue
samples. When the mice were given rmMFG-E8 i.p., the SOCS3
expression in peritoneal cells and spleen was significantly induced,
which become further elevated during endotoxemia by i.p. LPS
injection, but comparatively decreased in levels if they were pre-
treated with rmMFG-E8 followed by endotoxemia (Fig. 5C, 5D).
Since SOCS3 is a target gene of STAT3, hence modulation of
STAT3 phosphorylation during LPS and rmMFG-E8 pre-
Figure 4. MFG-E8 induces SOCS3 expression in macrophages. (A, B) RAW264.7 cells (4610
6 cells) and (C, D) mouse peritoneal macrophages
(2610
6 cells) were cultured in a 6-well cell culture plates, and treated with rmMFG-E8 (500 ng/mL) for 2 h followed by assessment of SOCS3 mRNA
expression and protein using real-time PCR and Western blot analysis, respectively. For real-time PCR, b-actin served as the internal control. To
examine protein level of SOCS3, a total of 25 mg of proteins extracted from each samples were subjected for Western-blotting. The image shown is
representative of results obtained from 3 independent experiments. The immunoblot was reprobed with mouse anti-b-actin Ab as loading control.
Densitometric evaluations (SOCS3/b-actin) are expressed as means 6 SE and compared by one-way ANOVA and SNK method: *P,0.05 vs. control. (E,
F) RAW264.7 cells (4610
6 cells) were cultured in a 6-well cell culture plate in presence of rmMFG-E8 (500 ng/mL) for 2 h, followed by LPS (10 ng/mL)
stimulation for 2 and 4 h, respectively, for SOCS3 mRNA expression by real-time PCR and protein levels by Western-blotting. In each experiment, b-
actin served as the internal control. Results are expressed as means 6 SE and compared by one-way ANOVA and SNK method. *P,0.05 vs. control;
#P,0.05 vs. LPS.
doi:10.1371/journal.pone.0027685.g004
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these conditions.
SOCS3 is activated via STAT3 pathway and targets NF-kB
p65 during rmMFG-E8 pre-treatment
Since the expression of SOCS3 is regulated by the upstream
transcription factor STAT3 [16], we used Static to treat
RAW264.7 cells and assessed rmMFG-E8 effects on SOCS3
expression to prove whether STAT3 is required for rmMFG-E8-
dependent SOCS3 expression. With an optimized dose of Static,
we noticed that the effects of rmMFG-E8 on SOCS3 activation
was diminished at its mRNA and protein levels (Fig. 6A, 6B),
confirming the requirement of STAT3 for MFG-E8-mediated
SOCS3 expression in macrophages.
SOCS3 protein contains an extraordinary ubiquitin ligase
activity for ubiquitination and proteosomal degradation of a
number of intracellular signaling components at which it interacts
[26,29]. As such, we aimed to determine whether the SOCS3 as
induced by rmMFG-E8 had any interaction with NF-kB p65
component. To attain this, RAW264.7 cells were treated with
rmMFG-E8 for 2 h, and then the p65 contents coupled to SOCS3
protein was determined by immunoprecipitation from the total
cellular extracts. As shown in Fig. 6C, RAW264.7 cells treated
with rmMFG-E8 clearly showed an increased level of p65 protein
immunoprecipitated with rmMFG-E8-induced SOCS3 protein.
Since SOCS3 induces the ubiquitination of the target protein, we
therefore assumed p65 protein might be ubiquitinated and
degraded after rmMFG-E8 pre-treatment. To prove our specu-
lation, proteins from the rmMFG-E8 pre-treated macrophages
were subjected to immunoprecipitation by using anti-p65 Ab,
followed by Western blotting using anti-ubiquitin Ab to assess
ubiquitination. According to our findings, we clearly noticed the
presence of ubiquitination in rmMFG-E8 pre-treated and p65
immunoprecipitated samples, while it was undetectable in control
samples (Fig. 6C).
Since NF-kB activation for target gene transcription requires
nuclear translocation of RelA/p65 subunit of NF-kB, we
therefore examined the effect of rmMFG-E8 on the cytosolic
and nuclear p65 protein levels in RAW264.7 cells treated with
LPS. Herein, we obtained four different features of cytosolic vs.
nuclear contents of p65 proteins depending on the combinations
used with rmMFG-E8 and LPS (Fig. 6D, 6E). At the resting state
of cells where neither rmMFG-E8 nor LPS was added, majority
of the p65 protein was localized at the cytoplasmic fraction
(Fig. 6D; lane 1, 2 from left), while undetected at the nuclear
portion (Fig. 6E; lane 1, 2 from left). Cells treated with rmMFG-
E8 showed decreased contents of cytoplasmic p65 (Fig. 6D; lane
3, 4 from left), instead of having any nuclear translocation of p65
Figure 5. In vivo effects of rmMFG-E8 on pSTAT3 and SOCS3 expression during endotoxemia. WT mice were injected with rmMFG-E8
(0.4 mg/20 g BW) via i.p. for 2 h and then endotoxemia was generated by an overdose of LPS (5 mg/kg BW) administration via i.p route. After 2 h of
LPS treatment mice were euthanized and total proteins were extracted from (A) peritoneal cells and (B) spleen to perform Western-blot using anti-
pSTAT3/STAT3 Abs. On the other hand, SOCS3 expression was assessed by real-time PCR using each of the cDNAs extracted from above samples of
(C) peritoneal cells and (D) spleen. b-actin served as an internal control. Data are expressed as means 6 SE and compared by one-way ANOVA and
SNK test from 3 independent experimental results. *P,0.05 vs. sham control;
#P,0.05 vs. endotoxemia.
doi:10.1371/journal.pone.0027685.g005
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proteolytic degradation during rmMFG-E8 treatment. In LPS-
treated conditions, the cytoplasmic p65 was found to be
decreased (Fig. 6D; lane 5, 6 from left), and correspondingly
the nuclear contents were increased (Fig. 6E; lane 5, 6 from left),
thus reflecting the nuclear translocation of p65 upon LPS
treatment for target gene expression. On the other hand, if
rmMFG-E8 pre-treated cells were stimulated by LPS, the
cytoplasmic (Fig. 6D; lane 7, 8 from left), and the nuclear
contents of p65 (Fig. 6E; lane 7, 8 from left) were comparatively
lower than in cells treated with LPS alone (Fig. 6D and 6E; lane
5, 6 from left). Since rmMFG-E8 pre-treatment caused reduction
of the cytoplasmic p65 contents, further LPS treatment in this
condition might decrease the nuclear translocation of p65,
resulting in decreased levels of target gene expression. Collec-
tively, these evidences strongly support the notion of MFG-E8-
mediated modulation of TLR4 signaling for attenuating inflam-
mation.
Figure 6. Interaction between NF-kB p65 and SOCS3 in rmMFG-E8-treated RAW264.7 cells. (A, B) RAW264.7 cells (4610
6 cells) were
grown into the 6-well culture plates and incubated for overnight in presence of Static (6.25 mM), followed by rmMFG-E8 (500 ng/mL) treatment for
2 h. Real-time PCR was done for SOCS3 mRNA expression (A) and Western blotting for SOCS3 protein levels (B). In each samples, the expression of b-
actin served as an internal control. (B) The protein level of SOCS3 was assessed by Western-blot from equal amounts (25 mg) of proteins and the
image shown is representative of 3 independent experiments. The immunoblot was reprobed with mouse anti-b-actin Ab as loading control.
Densitometric evaluations (SOCS3/b-actin) are expressed as means 6 SE and compared by one-way ANOVA and SNK method: *P,0.05 vs. DMSO
Control;
#P,0.05 vs. DMSO+rmMFG-E8. (C) RAW264.7 cells (4610
6 cells) were cultured in a 6-well cell culture plates, and treated with rmMFG-E8
(500 ng/mL) for 2 h. Proteins (80–100 mg) were immunoprecipitated using anti-mouse SOCS3 Ab and anti-mouse p65 Ab then subjected to Western-
blotting and immunoreacted with anti-p65 Ab for the detection of p65 protein and anti-ubiquitin Ab for detection of ubiquitination. The membrane
was re-probed with mouse anti-SOCS3 and anti-p65 Ab for determining SOCS3 and p65 contents. (D, E) RAW264.7 cells (4610
6 cells) were grown in 6-
well culture plates, and then pre-treated with rmMFG-E8 (500 ng/mL) for 2 h. After 30 min of LPS (10 ng/mL) stimulation (D) cytoplasmic and (E)
nuclear proteins were extracted to perform Western-blot using anti-p65 Ab. The membranes were reprobed with anti-GAPDH and Histone Abs for
evaluating the loading status of cytoplasmic and nuclear proteins, respectively. The images shown are representatives of 3 independent experiments.
*P,0.05 vs. control;
#P,0.05 vs. LPS.
doi:10.1371/journal.pone.0027685.g006
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Recently, MFG-E8 mediated therapeutic potential has been
reported in several disease models. Although majority of the
studies focused on the beneficial effects of MFG-E8 due to the
phagocytic clearance of apoptotic cells, a few studies also suggested
the role of MFG-E8 in innate-immune system regardless of its
roles in clearance of the apoptotic cells from the body [6,31,32,36].
Our study demonstrated the direct anti-inflammatory role of
MFG-E8 in terms of attenuating TNF-a production in mouse
peritoneal macrophages and RAW264.7 cells treated with LPS.
Since TNF-a is one of the early responsive pro-inflammatory
cytokines produced by macrophages during LPS treatment, the
anti-inflammatory therapeutic agents are mainly based on
neutralizing the excessive ectopic or systemic TNF-a release
[37]. Although the deleterious effects of TNF-a have been
reported immensely in various inflammatory conditions, the roles
of other pro-inflammatory cytokines and chemokines, such as,
interleukin-1b (IL-1b), IL-6, IL-12, IL-17 and IL-8 can not be
ignored; hence the therapeutic potential may be attained by
targeting these cytokines and chemokines. Using the murine
peritoneal macrophages we evaluated the effects of rmMFG-E8 in
terms of downregulating the production of other pro- and anti-
inflamatory cytokines, IL-1b and IL-10 after treatment with LPS
for 24 h. We found that LPS significantly induced the production
of IL-1b, but not IL-10 in murine peritoneal macrophages at 24 h,
and surprisingly the pre-treatment of rmMFG-E8 dramatically
decreased the IL-1b levels, even higher than that of TNF-a in
above conditions. Since, we could not detect IL-10 at 24 h of LPS
stimulation in mouse peritoneal macrophages, we therefore,
prolonged the incubation time up to 48 h, at which although
the IL-10 levels was detectable but there was no additional
increase with rmMFG-E8 pre-treatment (data not shown); hence
the possibility of MFG-E8-mediated anti-inflammatory functions
via IL-10 dependent STAT3 pathway may be refractory. In
support of our current in vitro findings, several in vivo studies have
also been conducted to prove the beneficial roles of exogenous
rmMFG-E8 in sepsis, colitis, gut, renal and hepatic ischemia and
reperfusion injuries by downregulating not only the TNF-a levels
but also other pro-inflammatory cytokines in target tissues and
serum samples [4,5,31].
In several in vitro and in vivo studies concerning the therapeutic
potential, rmMFG-E8 protein was given as a pre-treatment
regimen [31,34]. In our current project, rmMFG-E8 was given
as a pre-treatment regimen before LPS stimulation in macrophage
cells or generating endotoxemia in vivo. However in some in vivo
studies, instead of pre-treatment, rmMFG-E8 was given as post-
treatment or at the same time of inducing the disease, and the
beneficial roles of rmMFG-E8 in protecting the severity of the
diseases was observed [4,5]. Furthermore, in mouse model of
colitis, rmMFG-E8 was injected intravenously before the onset of
colitis and prolonged throughout the disease course as post
treatment [31] However, in an in vitro system to reveal the indirect
anti-inflammatory roles of rmMFG-E8 via accelerating the
phagocytosis of apoptotic cells, rmMFG-E8 was added to the co-
culture (apoptotic cells and phagocytes) as pre-treatment regimen
and then the LPS-stimulated TNF-a production was measured
[34]. From the above discussion, since the beneficial effects of
rmMFG-E8 can be observed in any of the pre- and post-treatment
condition, further studies using rmMFG-E8 as a post-treatment
regimen towards delineating the anti-inflammatory signal trans-
duction mechanisms might be of great interest.
TLRs are transmembrane proteins expressed by the cells of the
innate immune system, which recognize the pathogen associated
molecular patterns (PAMPs) and activate the signaling pathways
that launch immune and inflammatory responses against invaders
[38,39]. In mammals, the TLR family includes eleven proteins
(TLR1–TLR11). Different TLRs serve as receptors for diverse
ligands, including bacterial cell wall components, viral double-
stranded RNA and even small-molecule anti-viral or immuno-
modulatory compounds. In humans, TLR1, 2, 4, 5 and 6 are outer
membrane associated, and respond primarily to bacterial surface
associated PAMPs. The second group, TLR3, 7, 8 and 9 are found
on the surface of endosomes, where they respond primarily to
nucleic acid based PAMPs from viruses and bacteria. Upon
binding with their cognates, TLRs activate the core pathway
leading to activation of the transcription factor NF-kB and MAP
kinases, e.g., p38 and JNK [9,38,39]. Abnormal functioning of
TLR 2, 4, and 5 are noticed in sepsis, inflammatory bowel diseases
(IBD), atherosclerosis, asthma, rheumatoid arthritis, Alzheimer’s
disease, while the activated TLR 7, 8, and 9 are seen in SLE,
primary tumors, viral infection and skin lesions [40]. Targeting the
TLRs by using the respective neutralizing antibodies, and small-
molecule antagonists might also be prospects in disease therapy
[40]. Since we studied the potential anti-inflammatory roles of
MFG-E8 by utilizing the LPS induced murine model of
endotoxemia, we therefore highlighted the features of TLR4-
mediated innate immune responses upon rmMFG-E8 pre-
treatment.
The anti-inflammatory effects of MFG-E8 have been reported
in several studies [4,5,31]. In general, the phagocytic engulfment
of apoptotic cells creates an immune-tolerant state at the site of
inflammation by reducing the production of pro-inflammatory
cytokines and enhancing anti-inflammatory cytokines [41]. Based
on this concept, recent reports proposed an indirect mechanism
where MFG-E8 accelerated the phagocytic clearance of apoptotic
cells, thereby modulating the intra-cellular NF-kB, p38, ERK1/2
and JNK signaling for decreasing pro-inflammatory cytokine
production [34]. Depending on this view, exogenous administra-
tion of rmMFG-E8 attenuated inflammation by reducing pro-
inflammatory cytokines, TNF-a, IL-6 and IL-1b in sepsis as well as
other diseases where LPS-TLR4 signaling is predominant [4,5].
Interestingly, the high-mobility group box 1 protein (HMGB1) was
reported to interfere with the normal functioning of MFG-E8 by
competitively binding to the avb3-integrin [42]. Similarly, one
recent approach for MFG-E8-mediated anti-inflammatory role
has been proposed, where MFG-E8 was found to abrogate the
osteopontin (OPN)-mediated avb3-integrin outside-in signaling,
thereby inhibiting the synergistic effects for intensifying the
inflammation [31]. Besides these, herein we proposed a novel
mechanism for direct anti-inflammatory roles of MFG-E8 in terms
of attenuating the LPS-induced TNF-a production in macrophag-
es.
Treatment of murine macrophage cells by rmMFG-E8
significantly induced the STAT3 phosphorylation which in turn
up-regulated the down-stream SOCS3 gene expression. By using
the pSTAT3 inhibitor, we further proved that the induction of
SOCS3 was mediated via STAT3 pathway. However, it would be
interesting to elucidate how MFG-E8:avb3-integrin signaling leads
to STAT3 phosphorylation and SOCS3 upregulation in experi-
mental systems. In viable cells, MFG-E8 signaling is mediated
through the binding of its receptor, avb3-integrin, expressed by
variety of cells [1]. Integrin signaling is based on a complex
network of intra-cellular components which may lead to cross talk
among other pathways [43]. Once recognizing its ligand, avb3-
integrin signaling is transduced through a number of intracellular
molecules and protein tyrosine kinases, e.g., caveolin, vincullin,
talin, paxillin, focal adhesion kinase (FAK), Src, fyn and others
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STAT3, recent study has elucidated that OPN, one of the ligands
of avb3-integrin could activate the STAT3 signaling via binding to
the avb3-integrin for promoting the cell growth [44]. In another
study, the roles of avb3-integrin mediated Src tyrosine kinases for
inducing the activation of STAT3 has been well demonstrated in
intestinal epithelial cells, while the inhibition of Src prevented the
activation of STAT3 [45]. From the above evidences, the MFG-
E8-mediated STAT3 activation via avb3-integrin pathway was
anticipated.
During LPS stimulation, the cross-talk between TLR4 and
STAT3 was observed in several studies. Using mice deficient in
MyD88, Yamawaki et al. found that LPS-induced STAT3
phosphorylation in different organs were predominantly mediated
through MyD88 [46], suggesting the requirement of TLR4
signaling for efficient STAT3 activation. In our study, we noticed
LPS-dependent STAT3 phosphorylation initiated at 2 h and
prolonged at longer time to facilitate its role as a transcription
factor for down-stream signaling. Blocking pSTAT3 using Static
greatly attenuated the down-stream LPS effects for TNF-a
production, demonstrating synergistic action of STAT3 for LPS-
dependent TNF-a production in macrophages. Furthermore, we
noticed a remarkable feature when macrophages were pre-treated
with rmMFG-E8 and then stimulated with LPS, the LPS effect for
STAT3 activation was markedly reduced in a time-dependent
manner. We speculated this phenomenon might be due to the over
production of down-stream negative regulator during rmMFG-E8
pre-treatment which in turn modulated the LPS-dependent TLR4
signaling for STAT3 activation, and finally attenuated the
synergistic effects of STAT3 for TNF-a production. TLR4
signaling is under control of several negative regulators, which
are mostly activated by LPS. Modulation of negative regulators
either by over-expression or gene silencing may cause altered
TLR4 signaling [10,47]. SOCS families of proteins that are
induced by a wide range of stimuli serve as a negative regulator of
a number of signaling pathways, e.g., JAK/STAT, TLR, integrin,
insulin. Induced by various cytokines, growth factors and
hormones, STAT proteins serve as a pivotal transcription factor
for SOCS gene expression which in turn exerts negative regulation
on STAT signaling. Recent studies clearly revealed that how
SOCS1 interacts with the intracellular TLR4 adaptor molecules,
as well as the p65 of NF-kB, rendering them for ubiquitination and
proteosomal degradation [27–29]. Our findings demonstrated a
new insight where MFG-E8-treated macrophages clearly induced
SOCS3 expression, which in turn interacted with the NF-kB p65
protein and interfered with the TLR4 signaling as a potential
negative regulator (Fig. 7).
Although several therapeutic strategies are being proposed for
controlling sepsis induced endotoxemia, none have been found to
be totally effective. Conventional therapies for endotoxemia focus
on suppression and control of inflammation using corticosteroids,
and immune-modulating drugs [48,49]. Recently developed novel
cytokine antagonist therapies targeting TNF-a and IL-6 have been
found to be quite effective in certain types of endotoxemia [37].
Our findings of MFG-E8-mediated attenuation of LPS-induced
TNF-a production implicates an outstanding therapeutic potential
for ameliorating inflammatory consequences in various diseases,
hence improving the ‘‘quality of life’’.
In summary, we demonstrated the MFG-E8-mediated inhibi-
tion of LPS-induced TNF-a release in macrophages through the
mechanism involving STAT3-dependent SOCS3 activation,
which in turn highlighted the new approach of involving the
TLR4 negative regulatory system for generating the direct
beneficial effects of MFG-E8 on innate-immune systems.
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